115 related articles for article (PubMed ID: 38610044)
21. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.
Zhong FJ; Li YM; Xu C; Sun B; Wang JL; Yang LY
Clin Sci (Lond); 2021 Apr; 135(7):847-864. PubMed ID: 33755094
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression.
Duan Y; Wong W; Chua SC; Wee HL; Lim SG; Chua BT; Ho HK
Int J Oncol; 2016 Jan; 48(1):358-66. PubMed ID: 26573872
[TBL] [Abstract][Full Text] [Related]
23. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
24. NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway.
Xu S; Shu P; Zou S; Shen X; Qu Y; Zhang Y; Sun K; Zhang J
Cancer Med; 2018 Sep; 7(9):4701-4717. PubMed ID: 30085405
[TBL] [Abstract][Full Text] [Related]
25. MiR-490-5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells.
Xu B; Xu T; Liu H; Min Q; Wang S; Song Q
Pharmacology; 2017; 100(5-6):269-282. PubMed ID: 28810242
[TBL] [Abstract][Full Text] [Related]
26. The NCX1/TRPC6 Complex Mediates TGFβ-Driven Migration and Invasion of Human Hepatocellular Carcinoma Cells.
Xu J; Yang Y; Xie R; Liu J; Nie X; An J; Wen G; Liu X; Jin H; Tuo B
Cancer Res; 2018 May; 78(10):2564-2576. PubMed ID: 29500176
[TBL] [Abstract][Full Text] [Related]
27. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
28. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma.
Li W; Liao X; Ning P; Cao Y; Zhang M; Bu Y; Lv J; Jia Q
BMC Cancer; 2019 Apr; 19(1):395. PubMed ID: 31029128
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.
Lin B; Zhou X; Lin S; Wang X; Zhang M; Cao B; Dong Y; Yang S; Wang JM; Guo M; Huang J
J Mol Med (Berl); 2017 Nov; 95(11):1237-1249. PubMed ID: 28844099
[TBL] [Abstract][Full Text] [Related]
30. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling.
Zheng X; Gai X; Han S; Moser CD; Hu C; Shire AM; Floyd RA; Roberts LR
Genes Chromosomes Cancer; 2013 Mar; 52(3):225-36. PubMed ID: 23109092
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner.
Huang Z; Wen J; Yu J; Liao J; Liu S; Cai N; Liang H; Chen X; Ding Z; Zhang B
J Exp Clin Cancer Res; 2020 Aug; 39(1):150. PubMed ID: 32746934
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.
Chen Z; Zhou ZY; He CC; Zhang JL; Wang J; Xiao ZY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7222-7232. PubMed ID: 30468465
[TBL] [Abstract][Full Text] [Related]
33. CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.
Zong G; Xu Z; Zhang S; Shen Y; Qiu H; Zhu G; He S; Tao T; Chen X
Dig Dis Sci; 2016 Aug; 61(8):2303-2314. PubMed ID: 27074923
[TBL] [Abstract][Full Text] [Related]
34. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
35. The Role of TGF-β/SMAD Signaling in Hepatocellular Carcinoma: from Mechanism to Therapy and Prognosis.
Xin X; Cheng X; Zeng F; Xu Q; Hou L
Int J Biol Sci; 2024; 20(4):1436-1451. PubMed ID: 38385079
[TBL] [Abstract][Full Text] [Related]
36. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling.
Pu XY; Zheng DF; Shen A; Gu HT; Wei XF; Mou T; Zhang JB; Liu R
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):408-415. PubMed ID: 30201411
[TBL] [Abstract][Full Text] [Related]
37. FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway.
Shi JY; Ma LJ; Zhang JW; Duan M; Ding ZB; Yang LX; Cao Y; Zhou J; Fan J; Zhang X; Zhao YJ; Wang XY; Gao Q
BMC Cancer; 2017 Sep; 17(1):648. PubMed ID: 28903735
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of Ubiquitin-Specific Protease15 (USP15) Promotes Tumor Growth and Inhibits Apoptosis and Correlated With Poor Disease-Free Survival in Hepatocellular Carcinoma.
Yao XQ; Li L; Piao LZ; Zhang GJ; Huang XZ; Wang Y; Liang ZL
Technol Cancer Res Treat; 2020; 19():1533033820967455. PubMed ID: 33267707
[TBL] [Abstract][Full Text] [Related]
39. A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27.
Wu D; Wang Y; Yang G; Zhang S; Liu Y; Zhou S; Guo H; Liang S; Cui Y; Zhang B; Ma K; Zhang C; Liu Y; Sun L; Wang J; Liu L
Oncogene; 2020 Sep; 39(38):6099-6112. PubMed ID: 32811980
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
